• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Preventive Medicine Reports >Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population
【24h】

Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population

机译：高危人群中宫颈癌筛查的依从性因人乳头瘤病毒疫苗的接种状况而异

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cervical cancer screening has reduced the incidence of cervical cancer over the past 75years. The primary aim of this study was to determine if women receiving Gardasil? (HPV4 vaccine) participated in future cervical cancer screening at the same rate as that observed for unvaccinated women matched on birth year and health care campus. This is a retrospective cohort study of subjects selected from 27,786 females born from 1980 to 1992 who received health care in the Truman Medical Center safety net health system in Kansas City Missouri, USA. 1154 women 14–26years old who received at least one dose of HPV4 vaccine between 2006 and 2009 were chosen at random from the vaccine records. 1154 randomly chosen unvaccinated women were age and health campus matched to the vaccinated women and all were followed until July 1, 2013. Women who were screened after 21years and received three vaccine doses before 21years, had the lowest screening rate of 24%. Their only predictive factor for screening, compared to the unvaccinated, was being closer to 21years than 14years at vaccination (aOR=1.71 95% CI: 1.45, 2.00). Women vaccinated with three doses and screened at or after 21years had the highest screening rate of 84% predicting a six-fold increase in screening participation over no vaccine received (aOR=5.94 95% CI: 3.77, 9.35). Our results suggest that women who receive HPV4 vaccination closer to 21years, not 14, are more likely to participate in cervical cancer screening in an underserved US population. Highlights ? Screening rates are extremely low (24%) among those targeted for HPV vaccination. ? Screening rates are 84% if vaccinated at 21years or older. ? Only HPV vaccination at ages closer to 21years predicts screening participation. ? 3 dose recipients are more likely than unvaccinated to continue screening after NILM. ? Only 50% of vaccinated women continue to screen after a NILM result.
机译：在过去的75年中，子宫颈癌筛查降低了子宫颈癌的发病率。这项研究的主要目的是确定妇女是否接受加达西？ （HPV4疫苗）参与以后的子宫颈癌筛查的速度与在出生年份和医疗保健园区相匹配的未接种疫苗的妇女所观察到的相同。这是一项回顾性队列研究，研究对象是从1980年至1992年出生的27786名女性，这些女性在美国密苏里州堪萨斯城的杜鲁门医疗中心安全网卫生系统中接受过卫生保健。从疫苗记录中随机选择了1154名14-26岁的妇女，他们在2006年至2009年之间接受了至少一剂HPV4疫苗。随机选择了1154名未接种疫苗的妇女，这些妇女的年龄和健康状况与接种疫苗的妇女相匹配，所有患者均被随访至2013年7月1日。在21岁以后接受筛查并在21岁之前接受过三剂疫苗的妇女筛查率最低，为24％。与未接种疫苗相比，他们唯一的筛查预测因素是接种疫苗后14岁接近21岁（aOR = 1.71 95％CI：1.45，2.00）。接受三剂疫苗接种并在21岁或之后接受筛查的妇女的最高筛查率为84％，预计筛查参与率是未接种疫苗的六倍（aOR = 5.94 95％CI：3.77，9.35）。我们的结果表明，在未得到充分服务的美国人群中，接受HPV4疫苗接种接近21岁而非14岁的女性更有可能参与宫颈癌筛查。强调 ？在针对HPV疫苗接种的人群中，筛查率极低（24％）。 ？如果年龄在21岁或以上，则筛查率为84％。 ？只有接近21岁的HPV疫苗才能预测参与筛查。 ？ 3剂量接受者比未接种疫苗更有可能在NILM之后继续筛查。 ？在完成NILM结果后，只有50％的女性疫苗接种者继续进行筛查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号